A Technical Look At 2 Stocks: Nordstrom, Inc. (JWN), ImmunoGen, Inc. (IMGN)

Nordstrom, Inc. (NYSE:JWN) recorded a trading volume of 3.11 million shares, above its 90-day volume average of 2.07 million shares. The stock kicked off the session at $53.01 and later approached $53.95 with a change of 1.56%.

Nordstrom, Inc. (JWN) Analyst Opinion

Nordstrom, Inc. has a consensus hold rating from 22 Wall Street analysts, and the number of shares currently sold short amount to at least 11.59% of shares outstanding. The stock spiked 4.07% last month and is up 13.87 this year. Wall Street is only getting more bullish on the stock, with 5 of analysts who cover JWN having a buy-equivalent rating. Analysts have placed a $52.75 price target on Nordstrom, Inc., suggesting a -2.22% decline from recent close. It’s currently trading about -0.09% below its 52-week high.

Nordstrom, Inc. Earnings Surprise

Nordstrom, Inc. (JWN) surprised the stock market in its last reported earnings when it earned $0.51 a piece versus the consensus-estimated $0.43. Its revenue totaled $3.46 billion down -26.52% from the previous quarter.

Nordstrom, Inc. (NYSE:JWN) Intraday View

This stock (JWN) is ahead of its 52-week low with 42.75%. Its last month’s stock price volatility remained 2.52% which for the week stands at 2.5%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.38% and stays 7.41% away from its 50 days moving average. Over the last five days, shares have managed 3% gains and now is up 13.59% since hitting its 200-day moving average of $49.61. Nordstrom, Inc. (JWN) has made its way to a 12-month gain of 13.87%.

Turning to ImmunoGen, Inc. (NASDAQ:IMGN), its shares were trading at $11.26 a gain of $0.22, on the trading floor. The stock, after opening at $11.03, touched a high of $11.43 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.2. ImmunoGen, Inc. has 4 buy ratings, 2 holds and 0 sells even after the stock tumbled -16.03% from its high of $13.41 to a $1.79 billion market value through last close.

ImmunoGen, Inc. (IMGN) Consensus Price Target

The company’s consensus rating on Reuter’s scale slipped from 2.1 to 2 during a month. Analysts set a 12-month price target of $12 a share. The target implies a 6.57% spike from where the shares are currently trading. Also, the current price highlights a discount of 77.62% to analysts’ high consensus price target.

ImmunoGen, Inc. (NASDAQ:IMGN) Intraday Trading

The counter witnessed a trading volume of 2.16 million shares versus an average volume of 2.71 million shares during last trading session. Its last month’s stock price volatility remained 5.42% which for the week approaches 6.51%. The lowest price the stock reached in the last trading day was $11.01 and compares with the $4.80 52-week low. The stock recovered 134.58% since its low point and has performed 75.66% year-to-date.